Identification of kaempferol as an OSX upregulator by network pharmacology-based analysis of qianggu Capsule for osteoporosis

Ann Yehong Huang¹, Zhencheng Xiong², Kuankuan Liu², Yanan Chang², Li Shu², Guolan Gao³ and Chi Zhang²,4,5*

¹Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, United States, ²Central Laboratory, Peking University International Hospital, Beijing, China, ³Department of Obstetrics and Gynecology, Peking University International Hospital, Beijing, China, ⁴Department of Orthopedics, Peking University International Hospital, Beijing, China, ⁵Biomedical Engineering Department, Peking University, Beijing, China

Osteoporosis is the most common metabolic disease of skeleton with reduced bone density and weaker bone. Qianggu Capsule as a traditional chinese medicine has been widely used to treat osteoporosis. The potential pharmacological mechanism of its active ingredient Gusuibu is not well understood. The purpose of this work is to analyze the anti-osteoporosis function of Gusuibu based on network pharmacology, and further explore the potential mechanism of Qianggu Capsule. The active compounds and their corresponding targets of Gusuibu were obtained from TCMSP, TCMID, and BATMAN-TCM databases. Potential therapeutic targets for osteoporosis were obtained through DisGeNET, TTD, GeneCards, MalaCards, CTD, and OMIM databases. The overlapping targets of Gusuibu and osteoporosis were obtained. GO and KEGG pathway enrichment analysis were performed. The “Gusuibu-active compounds-target genes-osteoporosis” network and protein-protein interaction (PPI) network were constructed, and the top hub genes were screened by using the plug-in CytoHubba. Molecular docking was used to verify the binding activity of hub genes and key compounds. We identified 21 active compounds and 140 potential therapeutic targets that may be related to Gusuibu and 10 hub genes (AKT1, IL6, JUN, TNF, MAPK3, VEGFA, EGFR, MAPK1, CASP3, PTGS2). Molecular docking analysis demonstrated that four key active small molecules in Gusuibu (including Luteolin, Naringenin, Kaempferol, and Beta-sitosterol) have excellent binding affinity to the target proteins encoded by the top 10 hub genes. Our new findings indicated that one key active compound kaempferol activated the expression of osteoblast specific transcription factor OSX through JNK kinase pathway.

KEYWORDS
kaempferol, osteoporosis, qianggu capsule, gusuibu, OSX, network pharmacology
Introduction

Osteoporosis is the most common metabolic disease of skeleton with reduced bone density and weaker bone structure. Patients are more likely to have fractures with the pain and other complications, and the quality of life is dramatically affected (Zheng et al., 2020). Postmenopausal osteoporosis is one common form of primary osteoporosis. Osteoporosis is classified into the categories of "Gu Bi" and "Gu Lou" in the “Huang Di Nei Jing” of Traditional Chinese Medicine (TCM) theory (CSoOaBM, 2019). Bone metabolism is a continuous process, and bone mass will be gradually lost after the age of 35. People especially postmenopausal women and the elderly should pay more attention to osteoporosis prevention (Li et al., 2020a; Saul and Kosinsky, 2021). The fragility fractures induced by osteoporosis will lead to increased disability and mortality, resulting in a heavy family, social and economic burden (Kanis, 2002; Xiong et al., 2021). The commonly used anti-osteoporosis drugs include estrogen, calcium, vitamin D, bisphosphonates, and denosumab; however, the consequent adverse effects are still a challenge to be solved due to the increased duration of use and dose (Jackson and Mysiw, 2014). Therefore, it is needed to explore potential anti-osteoporosis drugs with high efficacy and safety.

It is well known that TCM has a long history of practice in China and other Asian countries to treat a wide range of diseases, including osteoporosis (Li et al., 2017a; Wei et al., 2017; Wu et al., 2017; Zhang et al., 2017; Ge et al., 2018; Li et al., 2020a; Li et al., 2020b; Liu et al., 2020; Zheng et al., 2020). Among those to treat osteoporosis, the clinically commonly used Traditional Chinese Medicine prescriptions include Qianggu Capsule, XianlingCubao Capsule, DuhuoJisheng Decoction, LiweiDihuang Pill, and Erxian Decoction (Li et al., 2017a; Wei et al., 2017; Wu et al., 2017; Ge et al., 2018; Li et al., 2020a). Qianggu Capsule (Drug approval number: Z20030007, Wei et al., 2017; Wu et al., 2017; Ge et al., 2018; Li et al., 2020a; Li et al., 2020b; Liu et al., 2020; Zheng et al., 2020). Among those to treat osteoporosis, the clinically commonly used Traditional Chinese Medicine prescriptions include Qianggu Capsule, XianlingCubao Capsule, DuhuoJisheng Decoction, LiweiDihuang Pill, and Erxian Decoction (Li et al., 2017a; Wei et al., 2017; Wu et al., 2017; Ge et al., 2018; Li et al., 2020a). Qianggu Capsule (Drug approval number: Z20030007, Qi-Huang Pharmaceutical CO. LTD., Beijing, China) is a China Food and Drug Administration (CFDA)-approved TCM for the treatment of osteoporosis and bone loss. The active ingredients in Qianggu Capsule are total flavonoids extracted from Rhizoma Drynariae (English name is Fortune’s Drynaria Rhizome, and Chinese name is Gusuibu), the dried rhizome of Drynaria fortune (Kunze) J. SM. (Wang et al., 2008; CSoOaBM, 2019). The active ingredient of Qianggu Capsules is the herbal Gusuibu. Gusuibu is still a kind of raw material, and there are many compounds in Gusuibu, including flavonoids. Studies have shown that the flavonoids in Gusuibu may treat osteoporosis by improving bone density and reducing bone loss (Zhang et al., 2017; Shen et al., 2020). However, the mechanism of function of many TCM cannot be elucidated due to the complexity of the ingredients in TCM.

In recent years, many researchers have started to use bioinformatics and network pharmacology to analyze the multi-component, multi-target and multi-pathway characteristics of TCM in order to elucidate mechanisms of its action, thus providing directions for further research (Shuai et al., 2020). Gusuibu contains a variety of components. Although some studies have suggested that total flavonoids play a key role in anti-osteoporosis (Wang et al., 2008; Zhang et al., 2017), the molecular mechanism has not been elucidated yet.

In this study we used a network pharmacology approach to analyze the key genes, active compounds and pathways in the anti-osteoporosis of Gusuibu, and further explored possible underlying molecular mechanisms. We identified one key active compound kaempferol in Gusuibu as an upregulator of osteoblast specific transcription factor OSX.

Materials and methods

Exploring potential pharmacodynamic compounds and relevant targets of gusuibu

Using TCM Systems Pharmacology (TCMSP, Version: 2.3, https://tcmspw.com/tcmsp.php) database (Ru et al., 2014), BATMAN-TCM platform (http://bionet.ncpsb.org/batman-tcmu/) (Liu et al., 2016) and TCM Integrated Database (TCMID, http://www.megabionet.org/tcmid/) (Huang et al., 2018), the corresponding compounds of Gusuibu and related information were obtained. The compounds retrieved in the previous step were screened for active compounds according to the absorption, distribution, metabolism and excretion (ADME) protocol (oral bioavailability (OB) ≥ 30 and drug-likeness (DL) ≥ 0.18) (Tsaioun et al., 2016; Sheng et al., 2020). The databases were then used to mine potential targets corresponding to the active compounds. The target proteins were then converted to the corresponding gene names and UniProt ID using the UniProt database (https://www.uniprot.org/) for “Homo sapiens” (UniProt Consortium, 2018).

Exploring the relevant targets of osteoporosis

The targets related to osteoporosis were obtained through retrieving GeneCards (https://www.genecards.org/) (Relevance score ≥10) (Stelzer et al., 2016), MalaCards (https://www.malacards.org/) (Rappaport et al., 2017), DisGeNet database (https://www.disgenet.org/, v7.0) (Score ≥ 0.01) (Piñero et al., 2020), Therapeutic Target Database (TTD) (http://db.idrblab.net/tdt/, Last update by 1 June 2020) (Wang et al., 2020), Comparative Toxicogenomics Database (CTD) (http://ctdbase.org/, Last update by June 2020) (Inference score ≥ 15) (Davis et al., 2020), and Online Mendelian Inheritance in Man (OMIM)
| Molecule ID | Molecule name                                      | OB (%) | DL   | 2D structure | InChI key                                      | PubChem CID |
|------------|---------------------------------------------------|--------|------|--------------|-----------------------------------------------|-------------|
| MOL000006  | Luteolin                                          | 36.16  | 0.25 | ![Luteolin](image) | IUPACNANSBPRGIPQ-UHFFFAOYSA-N                 | 5280445     |
| MOL000422  | Kaempferol                                         | 41.88  | 0.24 | ![Kaempferol](image) | IUPACWMYZQPIKC-UHFFFAOYSA-N                  | 5280863     |
| MOL004328  | Naringenin                                        | 59.29  | 0.21 | ![Naringenin](image) | IUPACVTWIRXFELQPI-ZDUSSCGKSA-N                | 439246      |
| MOL000358  | Beta-sitosterol                                    | 36.91  | 0.75 | ![Beta-sitosterol](image) | IUPACKZJWDPNLASS-VJSFXXLFSA-N                | 222284      |
| MOL000449  | Stigmasterol                                       | 43.83  | 0.76 | ![Stigmasterol](image) | IUPACHXVBMSMIARN-PHZYDNGSA-N                | 5280794     |
| MOL000492  | (+)-catechin                                       | 54.83  | 0.24 | ![(+)-catechin](image) | IUPACPFTAWBLQZVEMU-DZGQCGFSA-N              | 9064        |
| MOL000569  | Digallate                                         | 61.85  | 0.26 | ![Digallate](image) | IUPACCOVFWMINUOYRL-UHFFFAOYSA-N             | 341         |
| MOL001040  | (2R)-5,7-dihydroxy-2-([4-hydroxyphenyl]chroman-4-one | 42.36  | 0.21 | ![5,7-dihydroxy](image) | IUPACTVWIRXFELQPI-CYBMUIFWSA-N              | 667495      |
| MOL001978  | Aureusidin                                        | 53.42  | 0.24 | ![Aureusidin](image) | IUPACWBEFUVAYSFQUESA-PQMHYQBVSA-N           | 5281220     |

(Continued on following page)
TABLE 1 (Continued) Basic information of active compounds in Gusuibu.

| Molecule ID | Molecule name       | OB (%) | DL   | 2D structure | InChI key                          | PubChem CID |
|-------------|---------------------|--------|------|--------------|-----------------------------------|-------------|
| MOL002914   | Eriodyctiol (flavanone) | 41.35  | 0.24 | SBHXYTNGIZCORC-CYBMUJFWSA-N      |           |
| MOL005190   | Eriodictyol         | 71.79  | 0.24 | SBHXYTNGIZCORC-ZDUSSCGKSA-N      |           |
| MOL009061   | 22-Stigmasten-3-one | 39.25  | 0.76 | RTLUSWHIKFIQFU-ZBWVUXHAKA-N      |           |
| MOL009075   | Cycloartenone       | 40.57  | 0.79 | NAJCQAAOHKVCES-ZZOQNI6S-A-N      |           |
| MOL009078   | DavalliosideA_qt    | 62.65  | 0.51 | ZGIKMQJUZZSYOYY-QEIWDEWSA-N      | NR         |
| MOL009091   | Xanthogalenol       | 41.08  | 0.32 | ALGFNVZQNNNGPA-YRNVUSQSA-N      | 14309735   |
|             | Chitinone           |        |      | ITGPSXKMZIRAV-UHFFAOYSA-N       | 633072     |

(Continued on following page)
TABLE 1 (Continued) Basic information of active compounds in Gusuibu.

| Molecule ID | Molecule name  | OB (%) | DL  | 2D structure | InChI key | PubChem CID |
|-------------|----------------|--------|-----|--------------|-----------|-------------|
|             | Dihydrocaffeic acid |        |     | ![structure](image) | DZAUWHJDUNRCTF-UHFFFAOYSAN | 348154 |
|             | Kurarinone      |        |     | ![structure](image) | LTTQKYMNTNISSZ-MWTRKDXXA-N | 11982640 |
|             | Catechol        |        |     | ![structure](image) | YCIMHNLPFGHC-UHFFFAOYSAN | 289 |
|             | Naringin        |        |     | ![structure](image) | DFPMSGMTNDNHNZPHOTFPESA-N | 442428 |
|             | Campesterol     |        |     | ![structure](image) | SGNBVLWZMBQTH-PODYLUTMSA-N | 173183 |
|             | Gamma-Sitosterol |        |     | ![structure](image) | KJWDPNRRJALLNS-FRNIEFRESHA-N | 457801 |
|             | Narirutin       |        |     | ![structure](image) | HXTHSXYXVTHC-AJDQPGSA-N | 442431 |
|             | Hesperidin      |        |     | ![structure](image) | QUQPHWDTGMPREM-QJIBIFVCMSA-N | 10621 |

Abbreviations: OB, Oral bioavailability; DL, Drug-likeness; NR, not reported.
Enrichment analysis of GO and KEGG pathway

The cluster Profiler package in R (R 4.0.2 for Windows) was used to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis to explore biological processes and signaling pathways in Gusuibu for osteoporosis (Kanehisa et al., 2008; Yu et al., 2012; Consortium, 2015). An adjusted p-value of less than 0.05 was used to determine the enrichment term.

Implementation of molecular docking

The Sankey diagram (http://sankeymatic.com/) reveals the correspondence between herbs, components, and targets by constructing the interrelationship between the active compounds of Gusuibu and the top 10 hub genes. AutoDock Vina was used to perform molecular docking between the top 10 hub genes and key active ingredients to predict their binding affinity (Trott and Olson, 2010). The PDB format of the target proteins and the MOL2 format of active compounds could be obtained from the RCSB protein data (http://www.rcsb.org/) and the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) (Kanis, 2002). The smaller the molecular docking score, the more stable the binding affinity between target proteins and active compounds (Chang et al., 2020).

Cell culture

C2C12 mesenchymal stem cells (ATCC) were cultured in DMEM with 10% fetal bovine serum (FBS, Gibco), 100U/mL penicillin G sodium and 100 μg/ml streptomycin sulfate in a humidified atmosphere at 37°C. Cells were plated in 6-well plates, cultured to 60–80% confluence and treated with kaempferol.

Reverse transcription-quantitative PCR

Kaempferol (1,000 ng/ml; Sigma) was used to stimulate C2C12 cells for 24 h before harvest. TRIzol (Invitrogen Life Technologies, Carlsbad, CA, United States) was used to extract total RNA from cultured cells as previously described (Tang et al., 2012). RNA purity and integrity were determined by the RNA 6000 Nano assay with an Agilent Bioanalyzer 2,100 (Agilent Technologies, Santa Clara, CA). 1 μg total RNA was reverse transcribed into cDNA using the GoScript Reverse Transcription System (Promega Corp., Madison, WI, United States) based on the manufacturer protocol. qPCR was performed in triplicate.
using SYBR-Green SuperReal PreMix Plus [Tiangen Biotech (Beijing) Co., Ltd., China] and the iQ5 PCR system (Bio-Rad Laboratories, Inc., Hercules, CA, United States). The reaction conditions were as follows: 95°C for 30 s, and 40 cycles of 95°C for 10 s and 60°C for 30 s. Data were reported as cycle threshold (Ct) values. The 2−ΔΔCt method was used to compare the RNA expressions. RNA levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels.

**Statistical analysis**

All qPCR experiments were performed in triplicate. Data were expressed as the mean ± SD. Comparisons were made between groups by Student’s t test with p < 0.05 being considered as statistically significant.

**Results**

**Pharmacodynamic compounds and potential target genes of gusuibu**

A total of 131 compounds in Gusuibu (Rhizoma Drynariae) were obtained through the TCMSP database (Number: 71), TCMID database (Number: 53), and BATMAN-TCM platform (Number: 7). Based on the respective standards of TCMSP database (OB ≥ 30% and DL ≥ 0.18) and BATMAN-TCM platform (Score cutoff>20, adjusted p-value < 0.05) along with the existence of target proteins, a total of 24 active compounds of Gusuibu were screened. The corresponding target proteins were deduplicated, and a total of 331 target proteins were obtained. The UniProt database was used to convert the target proteins predicted by Gusuibu’s bioactive compounds into gene names. Table 1 includes the basic information of active compounds in Gusuibu.
Potential therapeutic targets of gusuibu in the treatment of osteoporosis

By searching the GeneCard, TTD, MalatCard, CTD, DisGeNET, and OMIM databases, a total of 1,578 potential therapeutic targets for osteoporosis were obtained. By constructing the Venn diagram of the targets regulated by Gusuibu’s active ingredients and the potential targets of osteoporosis, a total of 140 intersection targets were obtained, which are potential therapeutic targets of Gusuibu against osteoporosis as shown in Figure 1. Cytoscape software was used to construct the “Gusuibu-active compounds-target genes-osteoporosis” network for Gusuibu against osteoporosis as shown in Figure 2. There are three compounds (Cycloartenone, Narirutin, Naringin) corresponding to targets that are not intersecting genes, so there are 21 active compounds in the network.

PPI network construction and exploration of potential hub genes for gusuibu against osteoporosis

A total of 140 potential target genes of Gusuibu for treating osteoporosis were entered into the STRING database to obtain a PPI network, which involved 140 nodes and 2,199 edges (Figure 3). The data obtained was imported into Cytoscape software (version 3.7.2) for further visualization (Figure 4A). According to the 12 CytoHubba algorithms of Cytoscape software, the top 10 hub...
genes of Gusuibu for the treatment of osteoporosis were screened. A total of 37 different genes and the number of algorithms to which these genes belong were sorted in Table 2. The top 10 hub genes were consistent with the results of the Degree algorithm (Figure 4B). The Sankey diagram was constructed by using the top 10 ranked hub genes (AKT1, IL6, JUN, TFN, MAPK3, VEGFA, EGFR, MAPK1, CASP3, PTGS2) and the corresponding active compounds of Gusuibu. Luteolin targeted most of the hub genes while PTGS2 targeted most of the active compounds (Figure 5).

**Enrichment analysis of GO and KEGG pathway**

The Cluster Profiler package in R was used to perform GO enrichment analysis on 140 potential targets of Gusuibu in the treatment of osteoporosis. 2601 GO items (adjusted, p < 0.05) were obtained, including 2,398 biological process (BP) items, 75 cellular component (CC) terms and 128 molecular function (MF) items. As shown in Figure 6, the top 10 enrichment results of GO-BP, GO-CC, and GO-MF were visualized by bubble chart.

A total of 166 KEGG enriched pathways (adjusted, p < 0.05) were obtained through the above R package. As shown in Figure 7, the top 20 KEGG pathway enrichment terms were visualized by bubble chart.

We searched for osteoporosis in the KEGG database, and compared the retrieved relevant pathways with the enriched 166 pathways. A total of 50 pathways that may be related to osteoporosis were obtained, and we used Cytoscape software to construct a network diagram of potential target genes and pathways as shown in Figure 8.
Molecular docking

Based on the Sankey diagram results, molecular docking was performed between the top 10 target proteins (AKT1, IL6, JUN, TNF, MAPK3, VEGFA, EGFR, MAPK1, CASP3, PTGS2) and four key active compounds (Luteolin, Naringenin, Kaempferol, and Beta-sitosterol) using AutoDock Vina. As shown in Figure 9, a heatmap was used to visualize the strongest affinity docking scores of top 10 target proteins and 4 key active compounds. The binding energy between the top 10 target proteins and the active compound is about $-6.4$ to $-10.8$ kcal mol$^{-1}$, indicating that the key active compounds in Gusuibu bind well to the top 10 target proteins.
Kaempferol induced the expression of osteoblast genes

To explore the possible role of one key active compound kaempferol in osteoblast genes, we examined the effect of kaempferol on osteoblast differentiation related gene expressions. C2C12 cells were cultured and treated as indicated with kaempferol (1,000 ng/ml, Sigma) for 24 h. Total RNA was isolated and measured by real time RT-PCR. As shown in Figure 10, after kaempferol stimulation osteoblast specific transcription factor Osterix (OSX) expression was upregulated by about 6.1 folds, while the expression of OSX downstream osteoblastic gene osteocalcin (OCN) increased by 5.9 fold. These observations demonstrated that kaempferol induced OSX gene expression.

We asked which pathway was involved in kaempferol induced OSX gene expression. To explore molecular mechanisms of kaempferol effect on OSX expression, we used a loss-of-function approach to examine possible pathways involved. The selective inhibitors were used: SB203580 as a specific inhibitor for p38 MAPK pathway, and SP600125 is a specific inhibitor for JNK kinase pathway. C2C12 cells were treated with kaempferol. Different inhibitors were added in the culture medium. As shown in Figure 11, kaempferol treatment led to OSX expression increase by 10.8-fold. Addition of 50 μM SP600125 almost abolished the increment of OSX expression induced by kaempferol. Kaempferol-induced OSX activation remained unchanged after treatment with 10 μM SR203580. The data indicate that kaempferol-induced OSX activation is mediated through JNK kinase pathway.

Discussion

Osteoporosis has become an important health issue with aging (Zheng et al., 2020). For example, postmenopausal osteoporosis as a very common form of primary osteoporosis affects most postmenopausal women (Jackson and Mysiw, 2014). Due to severe side effects of current clinical osteoporosis drugs, more and more attention has been paid to possible drugs for the prevention and treatment of osteoporosis from natural products (Li et al., 2020a). Qianggu Capsule is a proprietary Traditional Chinese Medicine approved by CFDA to treat osteoporosis, and its active ingredient is total flavonoids of Rhizoma Drynariae (Gusuibu) (CSOaBM, 2019). Studies have shown that Qianggu Capsule may prevent and treat osteoporosis by improving bone density and reducing bone loss (Wei et al., 2017). The raw material of Qianggu Capsules is the flavonoids of the herbal Gusuibu, but the mixture is not a single compound at all, and the underlying mechanism is not clear yet. Based on the network pharmacological approaches such as databases mining, PPI network construction, GO and KEGG enrichment analysis and molecular docking validation, this study aims to analyze the active ingredients and potential targets of Gusuibu for osteoporosis treatment and to explore possible mechanisms of Qianggu Capsule active ingredients.

Based on the principle of ADME (setting OB ≥ 30 and DL ≥ 0.18) (Tsaioun et al., 2016), we searched three herbal databases, including TCMSP, TCMID and BATMAN-TCM platform, and screened 24 active compounds from Gusuibu (131 initially, after removing duplicates and null targets), and finally 331 corresponding target proteins were found. The protein name of the target protein obtained was converted into a gene ID through the UniProt database. Subsequently, we searched 6 disease-related databases (GeneCards, MalaCards, DisGeNET, TTD, CTD, and OMIM) and obtained a total of 1,578 potential therapeutic targets for osteoporosis. After constructing Venn diagrams with potential targets of Gusuibu, we obtained 140 potential target genes of Gusuibu for osteoporosis treatment. “Gusuibu-active compounds-target genes-osteoporosis” network was established, which involved 163 nodes and 432 interactions. The PPI network of potential therapeutic targets had also been constructed, involving 140 nodes and 2,199 edges. Based on the CytoHubba 12 algorithms of Cytoscape software (Degree, Clustering Coefficient, DMNC, Bottle Neck, MCC, MNC, Radiality, EPC, EcCentricity, Closeness, Betweenness, Stress), the top 10 hub genes were obtained, including AKT1, IL6, JUN, TNF, MAPK3,
FIGURE 6
Bubble chart of the top 10 GO enriched items.

FIGURE 7
Bubble chart of the top 20 KEGG pathway enriched items.
FIGURE 8
'Target genes–pathways' network. The cyan rectangle represents the potential target genes of Gusuibu against osteoporosis; the light blue ellipse represents the top 10 hub genes; the brown ellipse represents potential osteoporosis-related pathways.

FIGURE 9
Heatmap of molecular docking scores.
VEGFA, EGFR, MAPK1, CASP3, PTGS2. The physiological processes regulated by the proteins encoded by these core target genes mainly include inflammatory response, cell proliferation and differentiation, apoptosis, migration, cell cycle progression, angiogenesis, immune response, endocrine metabolism, bone metabolism, reproductive function, growth and nutrition. Therefore, based on these results, it may be speculated that Gusuibu may play a role in resisting osteoporosis through the multiple processes.

Sankey diagram showed the one-to-one correspondence between the top 10 hub genes and the corresponding active compounds contained in Gusuibu [Luteolin, Naringenin, Kaempferol, Beta-sitosterol, (+)-catechin, (R)-naringenin, Aureusidin, Digallate, Eriodictyol (flavanone), Eriodictyol, DavalliosideA_qt, Dihydrocaffeic acid, Kurarinone, Chitranone, Stigmasterol, Xanthogalenol]. Among them, Luteolin targeted nine hub genes, Naringenin targeted five hub genes, Kaempferol targeted five hub genes, Beta-sitosterol targeted three hub genes, and the others targeted one hub gene each. Luteolin is a flavonoid found in many herbal extracts with antioxidant, anti-inflammatory and anti-tumor activities, and has been shown to reduce glucocorticoid-induced osteoporosis by modulating the ERK/Lrp-5/GSK-3β signaling pathway in vitro and in vivo (Jing et al., 2019). We summarized the relevant literature exploring the possible mechanisms of Qianggu Capsule and its compounds for osteoporosis treatment (Liu et al., 2001; Wong et al., 2007; Wang et al., 2008; Chen et al., 2009; Hung et al., 2010; Guo et al., 2011; Huang et al., 2011; Ouyang et al., 2012; Li et al., 2017b; Wei et al., 2017; Zhang et al., 2017; Jing et al., 2019; Dong et al., 2020; Ruangsuriya et al., 2020; Shen et al., 2020; Liu et al., 2021) in Table 3.

We further analyzed the potential therapeutic genes of Gusuibu against osteoporosis by GO and KEGG pathway enrichment analysis. We used osteoporosis as a search term in the KEGG database and obtained ten directly related pathways, including osteoclast differentiation (hsa04380), AGE-RAGE signaling pathway in diabetic complications (hsa04933), Endocrine and other factor-regulated calcium reabsorption (hsa04961), Mineral absorption (hsa04978), Wnt pathway (hsa04310), MAPK pathway (hsa04010), Apoptosis (hsa04210), Chemokine pathway (hsa04062), T cell receptor pathway (hsa04660), and B cell receptor pathway (hsa04662).
Five of the top 10 hub genes (AKT1, TNF, MAPK3, JUN, MAPK1) are enriched in osteoclast differentiation. Eight of the top 10 hub genes (AKT1, IL6, CASP3, TNF, VEGFA, MAPK3, JUN, MAPK1) are enriched in AGE-RAGE pathway in diabetic complications. Eight of the top 10 hub genes (AKT1, CASP3, TNF, VEGFA, MAPK3, JUN, EGFR, MAPK1) are enriched in MAPK pathway. Six of the top 10 hub genes (AKT1, CASP3, TNF, VEGFA, MAPK3, JUN, MAPK1) are enriched in Apoptosis. Three of the top 10 hub genes (AKT1, MAPK3, MAPK1) are enriched in Chemokine pathway. Five of the top 10 hub genes (AKT1, TNF, MAPK3, JUN, MAPK1) are enriched in T cell receptor pathway. Four of the top 10 hub genes (AKT1, MAPK3, JUN, MAPK1) are enriched in B cell receptor pathway. The three pathways are not enriched including Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, and Wnt pathway.

To search for potentially relevant pathways, we obtained 50 enriched pathways as osteoporosis-related pathways and used Cytoscape software to construct the “pathway-gene” network. Studies have shown that there are many pathways associated with osteoporosis, which are mainly related to bone metabolism, inflammatory response, immune response, endocrine metabolism and apoptosis (Liu et al., 2020). Based on these analyses, Gusuibu may exert anti-osteoporosis effects through many pathways and hub genes.

As an osteoblast-specific transcription factor OSX is required for bone formation and osteoblast differentiation (Nakashima et al., 2002; Zhang et al., 2008). OSX was originally discovered as a BMP2 inducible gene in C2C12 mesenchymal stem cells, and OSX knock-out mice lack bone formation (Nakashima et al., 2002). OCN is a well-known downstream osteoblastic gene of OSX. There are three critical transcription factors required for osteoblast differentiation and bone formation: IHH, RUNX2 and OSX. OSX discovery as a master regulator of bone formation and osteoblast differentiation opens a new window to bone biology. As far as we know, this is the first study to discover that one active compound kaempferol in Gusuibu activated the expression of osteoblast specific transcription factor OSX through JNK kinase pathway.

### TABLE 3: Studies related to the regulation of bone metabolism by Qianggu Capsule and its active compounds.

| Chinese herbal medicine or compounds | Study | Organism | Possible pharmacological mechanisms | References |
|------------------------------------|-------|----------|------------------------------------|------------|
| Qianggu Capsule (total flavonoids of Rhizoma Drynariae) | Wei et al. (2017) | Human | Improving BMD | Wei et al. (2017) |
| | Zhang et al. (2017) | Human | Improving BMD | Zhang et al. (2017) |
| | Li et al. (2017b) | Rat | Enhancing the expression of TGF-β1 and promoting bone metabolism | Li et al. (2017b) |
| | Ouyang et al. (2012) | Human | Improving BMD | Ouyang et al. (2012) |
| | Huang et al. (2011) | Rat | Promoting the proliferation and decrease the apoptosis of osteoblasts by improving the ratio of Bcl-2 mRNA to Bax mRNA | Huang et al. (2011) |
| | Chen et al. (2009) | Rat | Promoting bone metabolism | Chen et al. (2009) |
| Gusuibu (RhizomaDrynariae) | Shen et al. (2020) | Rat | Enhancing angiogenic-osteogenic coupling during distraction osteogenesis by promoting type II vessel formation through PDGF-BB/ PDGFB-β instead of HIF-1α/VEGF axis | Shen et al. (2020) |
| | Hung et al. (2010) | Rat | Promoting osteoblast maturation by regulating bone differentiation-related gene expression | Hung et al. (2010) |
| | Wang et al. (2008) | Rat | Promoting bone healing | Wang et al. (2008) |
| | Wong et al. (2007) | Mouse | Promoting bone healing | Wong et al. (2007) |
| | Liu et al. (2001) | Rat | Promoting bone healing | Liu et al. (2001) |
| Luteolin | Jing et al. (2019) | Mouse | Luteolin reduced glucocorticoid-induced osteoporosis by modulating the ERK/Lrp-5/GSK-3β signaling pathway | Jing et al. (2019) |
| Naringin | Dong et al. (2020) | Rabbit | Naringin may be good natural BMP regulator in bone tissue engineering | Dong et al. (2020) |
| Naringin and Naringenin | Guo et al. (2011) | Mouse | Naringin and Naringenin revealed a double directional adjusting function of estrogenic and anti-estrogenic activities | Guo et al. (2011) |
| Kaempferol | Liu et al. (2021) | Rat | Kaempferol promotes BMSC osteogenic differentiation and improves osteoporosis by downregulating miR-10a-3p and upregulating CXCL12 | Liu et al. (2021) |
| Beta-sitosterol | Ruangsrurita et al. (2020) | Human | Beta-sitosterol triggered the molecules involved in bone formation and the molecules inhibiting bone resorption | Ruangsrurita et al. (2020) |

Abbreviations: BMD, bone mineral density; BMSC, bone marrow mesenchymal stem cell.
In summary, through network pharmacology, we explored the potential mechanisms by which Gusuibu exerts its anti-osteoporosis effects with a multi-component, multi-target, and multi-pathway profile. Potential therapeutic targets for Gusuibu to exert anti-osteoporosis effects include AKT1, IL6, JUN, TNF, MAPK3, VEGFA, EGFR, MAPK1, CASP3, PTGS2. Most of the key active compounds in Gusuibu are flavonoids, mainly including Luteolin, Naringenin, Kaempferol, and Beta-sitosterol. Interestingly, kaempferol was identified as an upregulator of OSX.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author contributions

CZ designed the study. AH, ZX, KL, YC, and LS performed the experiments. GG and CZ analyzed the data. CZ supervised the study. AH and ZX drafted the text. CZ corrected the manuscript.

References

Amberger, J., and Hamosh, A. (2017). Searching online mendelian inheritance in man (OMIM): A knowledgebase of human genes and genetic phenotypes. Curr. Protoc. Bioinform. 581, 1–2. doi:10.1002/cpbi.27

Chang, J., Liu, L., Wang, Y., Sui, Y., Li, H., and Feng, L. (2020). Investigating the multitarget mechanism of traditional Chinese medicine prescription for cancer-related pain by using network pharmacology and molecular docking approach. Evid. Based. Complement. Altern. Med. 2020, 7617261. doi:10.1155/2020/7617261

Chen, L., Chen, L., Chen, H., Guo, X., Xu, H., Zhang, G., et al. (2009). Skeletal biomechanical effectiveness of retinolic acid on induction of osteoporotic rats treated by alendronate and qianggu capsules. Zhonghui yi xue za zhi 89 (27), 1930–1933.

Chin, C., Chen, S., Wu, H., Ho, C., Ko, M., and Lin, C. (2014). cytoHuBBa: identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 511, 511. doi:10.1186/1752-0509-8-511

Consortium, T. G. O. (2015). Gene Ontology Consortium: Going forward. Nucleic Acids Res. 43, D1049-D1056. doi:10.1093/nar/gku1179

CSoOaBM, Research (2019). Guidelines for the diagnosis and management of primary osteoporosis (2017). Chin. J. Osteoporos. 25 (3), 281.

Davis, A., Grondin, C., Johnson, R., Scaky, D., Wiegars, J., Wiegars, T., et al. (2020). Comparative Toxicogenomics database (CTD): Update 2021. Nucleic Acids Res. 49, D1138-D1143. doi:10.1093/nar/gkaa891

Dong, G., Ma, T., Li, C., Chi, C., Su, C., Huang, C., et al. (2020). A study of Drynaria fortunei in modulation of BMP-2 signalling by bone tissue engineering. Turk. J. Med. Sci. 50 (5), 1444-1453. doi:10.3906/sag-2011-148

Ge, J., Xie, L., Chen, J., Li, S., Xu, H., Lai, Y., et al. (2018). Luweii dihuang pill treats postmenopausal osteoporosis with Shen kidney yin deficiency via janus kinase/ signal transducer and activator of transcription signal pathway by up-regulating cardiothoracic like cytokine factor 1 expression. Chin. J. Integr. Med. 24 (6), 415–422. doi:10.3736/si1655-016-2744-2

Guo, D., Wang, J., Wang, X., Luo, H., Zhang, H., Gao, D., et al. (2011). Double directional adjusting estrogenic effect of naringin from Rhizoma drynariar (Gusabai). J. Ethnopharmacol. 138 (2), 451-457. doi:10.1016/j.jep.2011.09.034

Huang, L., Xie, D., Yu, Y., Liu, H., Shi, Y., Shi, T., et al. (2014). Tcmid 2.0: A comprehensive resource for TCM. Nucleic Acids Res. 46, D1117-D1120. doi:10.1093/nar/gkt1028

Huang, Z., Ouyang, G., Xiao, L., Li, N., Gao, H., He, Y., et al. (2011). Effects of Drynaria total flavonoids on apoptosis of osteoblasts mediated by tumor necrosis factor-a. Zhong yi xi jie he xue bao 9 (2), 173–178. doi:10.3736/jcim20110210

Huang, T., Chen, T., Liao, M., Ho, W., Liu, D., Chuang, W., et al. (2010). Drynaria fortunei J. Sm. promotes osteoblast maturation by inducing differentiation-related gene expression and protecting against oxidative stress-induced apoptotic insults. J. Ethnopharmacol. 131 (1), 70–77. doi:10.1016/j.jep.2010.05.063

Jackson, R., and Mysiw, W. (2014). Insights into the epidemiology of postmenopausal osteoporosis: The women’s health initiative. Semin. Reprod. Med. 32 (6), 454–462. doi:10.1055/s-0034-1384629

Jing, Z., Wang, C., Yang, Q., Wei, X., Jin, Y., Meng, Q., et al. (2019). Luteolin attenuates glucocorticoid-induced osteoporosis by regulating ERK/Lrp-5/GSK-3β signaling pathway in vivo and in vitro. J. Cell. Physiol. 234 (4), 4472–4490. doi:10.1002/jcp.27252

Kanehisa, M., Araki, M., Goto, S., Hattori, M., Hirakawa, M., Itoh, M., et al. (2008). KEGG for linking genomes to life and the environment. Nucleic Acids Res. 36, D480–D484. doi:10.1093/nar/gkm882

Kanis, J. A. (2002). Diagnosis of osteoporosis and assessment of fracture risk. Lancet (London, Engl. 359–1936. doi:10.1016/S0140-6736(02)08761-5

Li, G., Xu, Q., Han, K., Yan, W., and Huang, C. (2020). Experimental evidence and network pharmacology-based analysis reveal the molecular mechanism of Tongzhiu dou capsule administered in coronary heart diseases. Biosci. Rep. 40 (10), BSR20201349. doi:10.1042/BSR20201349

Li, J., Jia, Y., Chai, L., Xu, M., Ma, S., Xu, L., et al. (2017). Effects of Chinese herbal formula erxian decoction for treating osteoporosis: A systematic review. Clin. Interv. Aging 12, 45–53. doi:10.2147/CIA.S117597

Li, J., Wang, W., Feng, G., Du, J., Kang, S., Li, Z., et al. (2020). Efficacy and safety of dahuan jiusheng decoction for postmenopausal osteoporosis: A systematic review and meta-analysis. Evol. Based. Complement. Altern. Med. 2020, 6957825. doi:10.1155/2020/6957825

Li, M., Wang, Y., Liao, N., Li, J., and Dong, Q. (2017). Changes of TGF-β1 expression during orthodontic tooth movement in rats with osteoporosis. Shanghai kou qiang yi xue 26 (1), 17–20.

Funding

This work was supported by the Beijing Municipal Science and Technology Commission (Grant Number: Z181100001818006).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
osteoblasts. J. Formos. Med. Assoc. = Taiwan yi zhi 106 (6), 383–388.

Liu, H., Yi, X., Tu, S., Cheng, C., and Luo, J. (2021). Kaempferol promotes BMSC osteogenic differentiation and improves osteoporosis by downregulating miR-10a-3p and upregulating CXCL12. Mol. Cell. Endocrinol. 520, 111074. doi:10.1016/j.mce.2020.111074

Liu, W., Jiang, Z., Chen, Y., Xiao, P., Wang, Z., Huang, T., et al. (2020). Network pharmacology approach to elucidate possible action mechanisms of Sinomenii Caulis for treating osteoporosis. J. Ethnopharmacol. 257, 112871. doi:10.1016/j.jep.2020.112871

Liu, Z., Guo, F., Wang, Y., Li, C., Zhang, X., Li, H., et al. (2016). BATMAN-TCM: A bioinformatics analysis tool for molecular mecha

Nakashima, K., Zhou, X., Kunkel, G., Zhang, D., Deng, J. M., Behringer, R. R., et al. (2002). The novel zinc finger-containing transcription factor osteoblast differentiation and bone formation. Cell. 108, 17–29. doi:10.1016/s0092-8674(01)00622-5

Ouyang, G., Feng, X., Xiao, L., Huang, Z., Xia, Q., and Zha, F. (2012). Effects of Chinese herbal medicine quinqua capsule on patients with rheumatoid arthritis-induced osteoporosis: A report of 82 cases. Zhong Xi Yi Jie He Xue Bao 10 (12), 1394–1399. doi:10.3736/jcim20121120

Pitillo, J., Ramírez-Anguita, J., Saich-Pitarach, J., Ronzano, F., Centeno, E., Sanz, F., et al. (2020). The DistGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 48, D845–D855. doi:10.1093/nar/gka1021

Rappaport, N., Twik, M., Plaschkes, I., Radyi, N., Iny Stein, T., Levitt, J., et al. (2017). MalaCards: An amalgamated human disease compendium with diverse disease exploration of synergistic mechanism of guanxin II formula (II) for coronary heart disease. Chin. J. Integr. Med. 23 (10), 8674(01)00622-5

Ruangsuriya, J., Charumanee, S., Jiranusornkul, S., Sirisa-Ard, P., Srichunyaung, B., Sirithunyalug, J., et al. (2020). Depletion of β-sitosterol and enrichment of quercetin and rutin in Cissus quadrangularis Linn fraction enhanced osteogenic but reduced osteoclastogenic marker expression. BMC Complement. Med. Ther. 20 (1), 105. doi:10.1186/s12906-020-02892-w

Saul, D., and Kooncey, R. (2021). Epigenetics of aging and aging-associated diseases. Int. J. Mol. Sci. 22 (1), E401. doi:10.3390/ijms2201401

Shen, Z., Chen, Z., Li, Z., Zhang, Y., Jiang, T., Lin, H., et al. (2020). Total flavonoids of rhizoma drynariae enhances angiogenic-osteogenic coupling during distraction osteogenesis by promoting type H vessel formation through PDGF-Bβ/PDGFR-β instead of HIF-1α/VEGF Axis. Front. Pharmacol. 11, 503524. doi:10.3389/fphar.2020.503524

Sheng, S., Yang, Z., Xu, F., and Huang, Y. (2020). Network pharmacology-based exploration of synergistic mechanism of guanxin II formula (II) for coronary heart disease. Chin. J. Integr. Med. 27, 106–114. doi:10.1007/s11553-020-3199-x

Shuai, Y., Jiang, Z., Yuan, Q., Tu, S., and Zeng, F. (2020). Deciphering the underlying mechanism of eucommia cortex against osteoporotic fracture by network pharmacology. Evitd Based. Complement. Altern. Med. 2020, 7049812. doi:10.1155/2020/7049812

Stelzer, G., Rosen, N., Plaschkes, I., Zimmerman, S., Twik, M., Fishilevich, S., et al. (2016). The GeneCards suite: From gene data mining to disease genome sequence analyses. Curr. Protoc. Bioinform. 541, 1–30. doi:10.1002/9780470015303.ch31.5